Overview

Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety of defibrotide in subjects with sickle cell disease (SCD)-associated acute chest syndrome (ACS).
Phase:
Phase 2
Details
Lead Sponsor:
New York Medical College
Collaborator:
Johns Hopkins University
Treatments:
Defibrotide